title: Clinical evaluation of metastases of malignant melanoma imaging with 99Tcm-glutathione and 99Tcm-anti-melanoma antibody: a comparative study.
abstract: The aim of this investigation was to test for the scintigraphic detection of metastases of malignant melanoma with a new radiopharmaceutical, 99Tcm-glutathione (99Tcm-GSH), in comparison with 99Tcm-anti-melanoma antibody (99Tcm-AMAb). Glutathione was labelled with 99Tcm by a Sn2+ reduction method with an efficiency of > 99% as determined by instant thin layer chromatography (ITLC). Anti-melanoma antibody was obtained as a kit from SORIN (Italy) and labelled with 99TcmO-4. Forty-three patients with a total of 55 biopsy-proven metastatic melanoma foci, 1 ocular melanoma and 20 benign pathologic foci, also confirmed by ultrasound, computed tomography and magnetic resonance imaging, were included in the study after giving their informed consent. Following the intravenous (i.v.) injection of 500 MBq 99Tcm-AMAb, scintigraphic images of the involved areas were obtained 6 h post-injection. Three days later, the same patients were given 500 MBq 99Tcm-GSH i.v. and images were obtained 6 and 24 h post-injection. The images were classified as positive (focal abnormal accumulation) or negative. Quantitative evaluation was also applied. Regions of interest were drawn over the involved areas and nearby soft tissues and the target-to-nontarget (T/NT) ratios obtained with 99Tcm-AMAb (T/NT: 1.92 +/- 0.2) and 99Tcm-GSH (T/NT: 1.84 +/- 0.2) were compared (0.1 < P < or = 0.3). The sensitivity (and specificity) of 99Tcm-AMAb and 99Tcm-GSH in the detection of malignant melanoma metastases were 91% (95%) and 84% (90%), respectively. Compared with 99Tcm-AMAb, the advantages of 99Tcm-GSH are lower levels of blood radioactivity, lower costs and easy in-house preparation. In conclusion, our results show that 99Tcm-GSH is a potentially useful radiopharmaceutical for the detection of metastases of malignant melanoma.
authors.affiliation: Department of Nuclear Medicine, Ege University, Bornova, Turkey.
authors.forename: Y
authors.initials: Y
authors.lastname: Duman
authors.forename: Z
authors.initials: Z
authors.lastname: Burak
authors.forename: M T
authors.initials: MT
authors.lastname: Ercan
authors.forename: A
authors.initials: A
authors.lastname: Dirlik
authors.forename: B C
authors.initials: BC
authors.lastname: Bilkay
authors.forename: Y
authors.initials: Y
authors.lastname: Akin
authors.forename: M
authors.initials: M
authors.lastname: Taner
authors.forename: C F
authors.initials: CF
authors.lastname: Bekdik
mesh_terms: D000912:Antibodies, Neoplasm; D005260:Female; D005978:Glutathione / Q000031:analogs & derivatives*; D006801:Humans; D007553:Isotope Labeling; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000276:immunology / Q000556:secondary*; D008875:Middle Aged; D016719:Radioimmunodetection / Q000379:methods*; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity; D013670:Sodium Pertechnetate Tc 99m; D013667:Technetium
chemical_list: D000912:Antibodies, Neoplasm; D011933:Reagent Kits, Diagnostic; C090285:technetium Tc 99m glutathione; D013667:Technetium; D013670:Sodium Pertechnetate Tc 99m; D005978:Glutathione